MX2015012808A - Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas. - Google Patents
Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas.Info
- Publication number
- MX2015012808A MX2015012808A MX2015012808A MX2015012808A MX2015012808A MX 2015012808 A MX2015012808 A MX 2015012808A MX 2015012808 A MX2015012808 A MX 2015012808A MX 2015012808 A MX2015012808 A MX 2015012808A MX 2015012808 A MX2015012808 A MX 2015012808A
- Authority
- MX
- Mexico
- Prior art keywords
- binding proteins
- expressing cells
- methods
- binding
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Abstract
La presente invención proporciona proteínas de unión de CD20 que se unen a e internalizan rápidamente antígenos de CD20 a partir de una ubicación de superficie celular al interior de una célula. Las proteínas de unión de CD20 de la invención comprenden una región de unión de CD20 y una región efectora de toxina Shiga. Ciertas de las proteínas de unión de CD20 descritas matan células que expresan CD20 sobre su superficie. Además, las proteínas de unión de CD20 actualmente descritas pueden comprender materiales exógenos adicionales y son capaces de entrega dirigida de estos materiales exógenos adicionales al interior de células que expresan CD20. Tales materiales adicionales pueden incluir péptidos, antígenos, enzimas y polinucleótidos. Estas proteínas de unión de CD20 tienen usos en métodos para internalizarse ellas mismas, matar de manera dirigida células que expresan CD20, entregar materiales exógenos en células que expresan CD20, y tratar una variedad de enfermedades que involucran células que expresan CD20, tales como cáncer y desórdenes inmunes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361777130P | 2013-03-12 | 2013-03-12 | |
PCT/US2014/023198 WO2014164680A1 (en) | 2013-03-12 | 2014-03-11 | Cd20-binding immunotoxins for inducing cellular internalization and methods using same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015012808A true MX2015012808A (es) | 2016-05-31 |
Family
ID=50625074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015012808A MX2015012808A (es) | 2013-03-12 | 2014-03-11 | Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas. |
Country Status (21)
Country | Link |
---|---|
US (4) | US10450354B2 (es) |
EP (4) | EP2970478B1 (es) |
JP (6) | JP6548630B2 (es) |
KR (2) | KR101990341B1 (es) |
CN (2) | CN111363047A (es) |
AU (1) | AU2014249107C1 (es) |
CA (2) | CA2902324A1 (es) |
CY (1) | CY1123138T1 (es) |
DK (1) | DK2970487T3 (es) |
ES (2) | ES2808726T3 (es) |
HK (1) | HK1215268A1 (es) |
HR (1) | HRP20200553T1 (es) |
HU (1) | HUE049470T2 (es) |
IL (3) | IL240433B (es) |
LT (1) | LT2970487T (es) |
MX (1) | MX2015012808A (es) |
PL (1) | PL2970487T3 (es) |
PT (1) | PT2970487T (es) |
RS (1) | RS60280B1 (es) |
SI (1) | SI2970487T1 (es) |
WO (2) | WO2014164680A1 (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104987416A (zh) | 2008-05-23 | 2015-10-21 | Siwa有限公司 | 促进再生的方法、组合物及设备 |
EP2970478B1 (en) | 2013-03-12 | 2020-05-06 | Molecular Templates, Inc. | Cd20-binding immunotoxins for inducing cellular internalization and methods using same |
US20210138076A2 (en) * | 2014-01-27 | 2021-05-13 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
WO2015113005A1 (en) | 2014-01-27 | 2015-07-30 | Molecular Templates, Inc. | Mhc class i epitope delivering polypeptides |
WO2015191764A1 (en) | 2014-06-11 | 2015-12-17 | Molecular Templates, Inc. | Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same |
EP3102245B1 (en) * | 2014-02-05 | 2021-09-08 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
CN106414503A (zh) | 2014-03-11 | 2017-02-15 | 分子模板公司 | 包含邻近氨基酸端的志贺毒素a亚基效应子区和细胞靶向性免疫球蛋白型结合区的蛋白 |
ES2723774T3 (es) | 2014-03-11 | 2019-09-02 | Molecular Templates Inc | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal |
US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
US20150328263A1 (en) * | 2014-05-14 | 2015-11-19 | University Of Maryland, Baltimore | Cardiac stem cells for cardiac repair |
US10387178B2 (en) * | 2014-10-29 | 2019-08-20 | Red Hat Israel, Ltd. | Idle based latency reduction for coalesced interrupts |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
CN108064247B (zh) | 2015-02-05 | 2022-06-03 | 分子模板公司 | 包含志贺毒素a亚基效应物区域的多价cd20结合分子及其富集组合物 |
EP3303373B1 (en) | 2015-05-30 | 2020-04-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
AU2016297920A1 (en) * | 2015-07-26 | 2018-01-18 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes |
WO2017143073A1 (en) | 2016-02-19 | 2017-08-24 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
WO2017153402A1 (en) * | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding single domain antibodies |
CN109311975A (zh) | 2016-04-15 | 2019-02-05 | Siwa有限公司 | 用于治疗神经退行性紊乱的抗age抗体 |
US11603394B2 (en) * | 2016-10-04 | 2023-03-14 | University Of Florida Research Foundation, Incorporated | Targeted effector proteins and uses thereof |
US11084859B2 (en) | 2016-10-24 | 2021-08-10 | Orionis Biosciences BV | Targeted mutant interferon-gamma and uses thereof |
EP3535392B1 (en) * | 2016-11-02 | 2024-03-27 | Universität Basel | Immunologically discernible cell surface variants for use in cell therapy |
EP3551046B1 (en) | 2016-12-07 | 2023-07-19 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
US20210008208A1 (en) | 2016-12-07 | 2021-01-14 | Molecular Templates, Inc. | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
US20200024312A1 (en) | 2017-01-25 | 2020-01-23 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes |
CA3050601A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzm | Immune-cell targeted bispecific chimeric proteins and uses thereof |
EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
JP2020516648A (ja) | 2017-04-13 | 2020-06-11 | シワ コーポレーション | ヒト化モノクローナル終末糖化産物抗体 |
JP7301757B2 (ja) * | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
SG11202002533QA (en) * | 2017-09-22 | 2020-04-29 | Kite Pharma Inc | Chimeric polypeptides and uses thereof |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
CA3097178A1 (en) | 2018-04-17 | 2019-10-24 | Molecular Templates, Inc. | Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
CN112955459A (zh) * | 2018-10-23 | 2021-06-11 | 拜斯科技术开发有限公司 | 双环肽配体和其用途 |
EP3883634A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
WO2020154475A1 (en) | 2019-01-23 | 2020-07-30 | Molecular Templates, Inc. | Proteins comprising modified immunoglobulin variable light chains |
US11713347B2 (en) | 2019-01-23 | 2023-08-01 | Millennium Pharmaceuticals, Inc. | CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors |
CN115925972A (zh) | 2019-02-18 | 2023-04-07 | Atb治疗公司 | 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法 |
CA3133643A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
TW202110485A (zh) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
CA3149621A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
US20210155671A1 (en) | 2019-11-24 | 2021-05-27 | Molecular Templates, Inc. | Uses of cd20-binding molecules and additional therapeutic agents |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
IL300246A (en) | 2020-08-05 | 2023-03-01 | Dragonfly Therapeutics Inc | Antibodies directed to EGFR and their use |
WO2022133092A1 (en) * | 2020-12-16 | 2022-06-23 | Molecular Templates, Inc. | Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector |
EP4308242A1 (en) | 2021-03-17 | 2024-01-24 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
WO1991009871A1 (en) | 1989-12-22 | 1991-07-11 | Seragen Incorporated | Hybrid molecules having translocation region and cell-binding region |
US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
US5621083A (en) | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
EP0700444B1 (en) | 1993-05-12 | 2003-04-02 | XOMA Corporation | Immunotoxins comprising gelonin and an antibody |
AU723268B2 (en) | 1996-09-09 | 2000-08-24 | Zealand Pharma A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
WO1998011229A2 (en) | 1996-09-10 | 1998-03-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
CA2222993A1 (en) | 1998-02-04 | 1999-08-04 | The Ontario Cancer Institute | A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries |
DK1098664T3 (da) | 1998-07-22 | 2003-11-17 | Osprey Pharmaceuticals Ltd | Sammensætninger og deres anvendelser til at behandle sekundær vævsskade og andre inflammatoriske tilstande og forstyrrelser |
US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US7267973B2 (en) | 2000-03-22 | 2007-09-11 | Sibtech, Inc. | Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor |
US20010031485A1 (en) | 2000-03-22 | 2001-10-18 | Sibtech, Inc. | Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments |
BR0110610A (pt) | 2000-04-11 | 2003-04-29 | Genentech Inc | Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados |
EP2281837B1 (en) | 2001-08-10 | 2016-10-05 | Aberdeen University | Antigen binding domains from fish |
ATE471371T1 (de) | 2002-02-04 | 2010-07-15 | Yoshida Hideo | Antikrebsmittel mit verotoxinvarianten |
EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
US7875586B2 (en) * | 2002-12-20 | 2011-01-25 | The Johns Hopkins University | Treatment of metastatic colon cancer with b-subunit of shiga toxin |
US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
AU2004317555B2 (en) | 2004-03-26 | 2011-12-01 | Molecular Templates, Inc. | Library of toxin mutants, and methods of using same |
RU2007117752A (ru) | 2004-10-13 | 2008-11-20 | Аблинкс Н.В. (Be) | Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера |
NZ561883A (en) | 2005-03-23 | 2010-11-26 | Genmab As | Antibodies against CD38 for treatment of multiple myeloma |
EP3673919A1 (en) * | 2005-06-14 | 2020-07-01 | Amgen Inc. | Self-buffering protein formulations |
WO2007014238A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | Single dose use of cd20-specific binding molecules |
EP2402367A1 (en) | 2005-09-26 | 2012-01-04 | Molecular Templates, Inc. | Library from toxin mutants, and methods of using same |
GB0524788D0 (en) | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
AU2007339753A1 (en) | 2006-12-29 | 2008-07-10 | Osprey Pharmaceuticals Usa, Inc. | Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof |
FR2915398B1 (fr) * | 2007-04-25 | 2012-12-28 | Lab Francais Du Fractionnement | "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse" |
EP2570425B1 (en) | 2007-09-04 | 2017-08-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Deletions in domain II of Pseudomonas exotoxin A that reduce non-specific toxicity |
US20090148904A1 (en) | 2007-11-13 | 2009-06-11 | Mayfield Stephen P | Production of cytotoxic antibody-toxin fusion in eukaryotic algae |
AU2008328784B2 (en) | 2007-11-27 | 2014-03-27 | Ablynx N.V. | Immunoglobulin constructs |
CA2731255C (en) * | 2008-07-21 | 2018-06-05 | David M. Goldenberg | Structural variants of antibodies for improved therapeutic characteristics |
WO2010085539A1 (en) * | 2009-01-23 | 2010-07-29 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods and compositions based on shiga toxin type 2 protein |
US20120258104A1 (en) | 2009-07-22 | 2012-10-11 | Cenix Bioscience Gmbh | Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes |
GB201013989D0 (en) | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
PL219845B1 (pl) | 2011-01-05 | 2015-07-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
EP2667898A1 (en) * | 2011-01-26 | 2013-12-04 | Cenix Bioscience GmbH | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
SG191977A1 (en) * | 2011-02-01 | 2013-08-30 | Genmab As | Human antibodies and antibody-drug conjugates against cd74 |
US8895006B2 (en) | 2011-03-04 | 2014-11-25 | Rutgers, The State University Of New Jersey | Ricin ribosome binding protein compositions and methods of use thereof |
US10683362B2 (en) | 2011-05-06 | 2020-06-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant immunotoxin targeting mesothelin |
PL397167A1 (pl) | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
EP2970478B1 (en) | 2013-03-12 | 2020-05-06 | Molecular Templates, Inc. | Cd20-binding immunotoxins for inducing cellular internalization and methods using same |
GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
WO2015113005A1 (en) | 2014-01-27 | 2015-07-30 | Molecular Templates, Inc. | Mhc class i epitope delivering polypeptides |
EP3102245B1 (en) | 2014-02-05 | 2021-09-08 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
ES2723774T3 (es) | 2014-03-11 | 2019-09-02 | Molecular Templates Inc | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal |
CN106414503A (zh) | 2014-03-11 | 2017-02-15 | 分子模板公司 | 包含邻近氨基酸端的志贺毒素a亚基效应子区和细胞靶向性免疫球蛋白型结合区的蛋白 |
EP3303373B1 (en) * | 2015-05-30 | 2020-04-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
-
2014
- 2014-03-11 EP EP14720298.0A patent/EP2970478B1/en active Active
- 2014-03-11 CN CN202010215621.7A patent/CN111363047A/zh active Pending
- 2014-03-11 MX MX2015012808A patent/MX2015012808A/es unknown
- 2014-03-11 EP EP14726015.2A patent/EP2970487B1/en active Active
- 2014-03-11 HU HUE14726015A patent/HUE049470T2/hu unknown
- 2014-03-11 EP EP20154062.2A patent/EP3666795A1/en not_active Withdrawn
- 2014-03-11 ES ES14720298T patent/ES2808726T3/es active Active
- 2014-03-11 AU AU2014249107A patent/AU2014249107C1/en active Active
- 2014-03-11 ES ES14726015T patent/ES2800630T3/es active Active
- 2014-03-11 SI SI201431553T patent/SI2970487T1/sl unknown
- 2014-03-11 WO PCT/US2014/023198 patent/WO2014164680A1/en active Application Filing
- 2014-03-11 US US14/774,609 patent/US10450354B2/en active Active
- 2014-03-11 CA CA2902324A patent/CA2902324A1/en active Pending
- 2014-03-11 KR KR1020157023206A patent/KR101990341B1/ko active IP Right Grant
- 2014-03-11 CA CA2902432A patent/CA2902432A1/en not_active Abandoned
- 2014-03-11 LT LTEP14726015.2T patent/LT2970487T/lt unknown
- 2014-03-11 US US14/774,130 patent/US20160068577A1/en not_active Abandoned
- 2014-03-11 WO PCT/US2014/023231 patent/WO2014164693A2/en active Application Filing
- 2014-03-11 PT PT147260152T patent/PT2970487T/pt unknown
- 2014-03-11 DK DK14726015.2T patent/DK2970487T3/da active
- 2014-03-11 RS RS20200451A patent/RS60280B1/sr unknown
- 2014-03-11 EP EP20155659.4A patent/EP3683240A1/en not_active Withdrawn
- 2014-03-11 PL PL14726015T patent/PL2970487T3/pl unknown
- 2014-03-11 JP JP2016501176A patent/JP6548630B2/ja active Active
- 2014-03-11 KR KR1020197016790A patent/KR102110127B1/ko active IP Right Grant
- 2014-03-11 JP JP2016501171A patent/JP6472784B2/ja active Active
- 2014-03-11 CN CN201480013350.XA patent/CN105051067B/zh active Active
-
2015
- 2015-08-09 IL IL240433A patent/IL240433B/en active IP Right Grant
-
2016
- 2016-03-22 HK HK16103313.6A patent/HK1215268A1/zh unknown
-
2018
- 2018-02-20 US US15/899,428 patent/US20180258144A1/en not_active Abandoned
-
2019
- 2019-01-23 JP JP2019009370A patent/JP6745923B2/ja active Active
- 2019-06-25 JP JP2019117230A patent/JP6896021B2/ja active Active
- 2019-09-12 US US16/568,638 patent/US20200002387A1/en not_active Abandoned
- 2019-11-18 IL IL270745A patent/IL270745B/en active IP Right Grant
-
2020
- 2020-04-04 HR HRP20200553TT patent/HRP20200553T1/hr unknown
- 2020-05-19 CY CY20201100456T patent/CY1123138T1/el unknown
- 2020-08-04 JP JP2020132606A patent/JP2020193205A/ja active Pending
-
2021
- 2021-06-08 JP JP2021095748A patent/JP2021164456A/ja active Pending
- 2021-06-14 IL IL283969A patent/IL283969B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015012808A (es) | Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas. | |
MX2016011821A (es) | Proteinas que comprenden regiones efectoras de subunidad a de toxina shiga proximas a amino terminal y regiones de union de tipo inmunoglobulina de direccionamiento selectivo celular. | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
MX2022008184A (es) | Anticuerpos anti pd-1 y anti-lag3 para usarse en el tratamiento de cancer. | |
PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
MY192474A (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
MX2019006598A (es) | Celulas asesinas naturales modificadas geneticamente y sus usos. | |
WO2014062697A3 (en) | Drug delivery conjugates containing unnatural amino acids and methods for using | |
PH12020550600A1 (en) | Novel engineered t cell receptors and immune therapy using the same | |
MY174259A (en) | Antigen binding protein and its use as addressing product for the treatment of cancer | |
PH12017501728A1 (en) | Chimeric antigen receptors targeting b-cell maturation antigen | |
MX2019001769A (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
SG11201807936VA (en) | Cell injury inducing therapeutic drug for use in cancer therapy | |
EA201790986A1 (ru) | Антитела к cd73 и их применения | |
MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
AU2016335217A8 (en) | Antigen receptors and uses thereof | |
MX352738B (es) | Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos. | |
PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
WO2015069922A3 (en) | Alk antibodies, conjugates, and chimeric antigen receptors, and their use | |
WO2013053008A3 (en) | Molecules which bind clec9a | |
MX2021002144A (es) | Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer. | |
PH12020550035A1 (en) | Universal abt compounds and uses thereof | |
MY196747A (en) | Cell injury inducing therapeutic drug for use in cancer therapy | |
MX2019011717A (es) | Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos. | |
WO2018202921A3 (en) | Nanostructured proteins and uses thereof |